The company aims to expand its presence significantly with this new product line
Witnesses massive response in the initial launch phase
KeyCi empowers individuals through skincare, rooted in science and sustainability
New Delhi, April 14, 2026: Iberia Pharmaceuticals, a leading name in pharmaceutical industry, has announced an overwhelming response to the initial launch phase of KeyCi – its science-backed skincare brand. The response reflects a growing consumer shift toward research-driven skin care that aims to set new standards by offering effective, sustainable and inclusive solutions that inspire confidence, conscious beauty, and foster long-term trust. Within months of launch, the brand has reached thousands of consumers across the country, with products designed to deliver affordable luxury, premium-quality skincare that support barrier repair, hydration, and long-term skin health.
KeyCi, designed for modern consumers aged 18–45 offers high-performance, dermatologically tested products that are vegan, cruelty-free, alcohol-free, paraben-free and FDA approved. Developed by dermatologists and supported by pharma-grade R&D, KeyCi’s range of four products – Barrier Repair Ultra Hydrating Facial Cleanser, Skin Brightening Face Serum, Barrier Repair Ultra Hydrating Skin Moisturizer and InvisiBlock Advanced Fluid Sunscreen SPF 50 PA ++++ aim to bridge the gap between daily skincare and clinical-grade performance with formulations that address Indian skin specifically. Its liposomal delivery systems enable deeper penetration, sustained release, and improved bioavailability, offering clinically proven results.
Gender neutral and suitable for all skin types, KeyCi has been in development for several years, with Iberia’s in-house research team working closely with dermatologists and clinical partners to create products that are safe, effective and suited to local conditions.
“Our vision is to become a global leader in clean beauty, and we aim to set new standards in skincare. The response we have received during the initial phase has exceeded our expectations and validates the trust that consumers place in our formulations about science-backed skincare. Our focus has been on building formulations grounded in dermatological research and pharmaceutical standards while ensuring they are suited to Indian climatic conditions and lifestyles.” said Nitin Jain, Founder and Managing Director, Iberia Pharmaceuticals.
“Our aim with KeyCi has been to bring together clinical research, safe formulations and responsible production practices. Following the strong initial traction, the company plans to introduce new products within the portfolio in the near future. The early market response also reinforces the demand for skincare that is both scientifically formulated and mindful of sustainability.” said Saurav Ojha, Co-Founder & Whole-Time Director, Iberia Pharmaceuticals.
Iberia Pharmaceuticals has established itself as a trusted name in pharma-grade skincare through brands such as Sesderma, Mediderma, Dermpix, Metacare, and Noreva. Iberia has been in service of the pharmaceutical needs of India and the world for more than a few decades. Iberia embraces global brands that use nanotechnology to develop formulations that deliver active ingredients with precision and enhanced efficacy. What started as a single vision, it has blossomed into a full-scale operation with advanced manufacturing facilities and science, including R&D facilities, and nationwide distribution.
